Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
18 hedge funds and large institutions have $298K invested in Statera Biopharma, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
3% less capital invested
Capital invested by funds: $306K → $298K (-$8K)
10% less funds holding
Funds holding: 20 → 18 (-2)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$38.3K |
| 2 |
BlackRock
New York
|
+$5.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$32K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$28.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.46K |
| 4 |
Morgan Stanley
New York
|
-$1.66K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$83 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $132K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $56K | +$38.3K | +23,100 | +194% |
|
|
LTFS
3
Ladenburg Thalmann Financial Services
Miami,
Florida
| $55K | – | – | – |
|
4
Geode Capital Management
Boston,
Massachusetts
| $26K | – | – | – |
|
|
VKH
5
Virtu KCG Holdings
New York
| $22K | -$28.7K | -17,286 | -56% |
|
|
6
BlackRock
New York
| $5K | +$5.88K | +3,541 | New |
|
|
IA
7
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
|
WA
8
Winfield Associates
Cleveland,
Ohio
| $1K | – | – | – |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$32K | -22,216 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$3.46K | -2,086 | -95% |
|
|
11
Morgan Stanley
New York
| – | -$1.66K | -1,000 | -95% |
|
|
12
Bank of America
Charlotte,
North Carolina
| – | -$83 | -50 | -33% |
|
STAB Hedge Fund Activity: Q1 2017 in Review
18 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q1 2017, worth a combined $298K — down 2.6% from $306K a quarter earlier.
Fund positioning in STAB was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $38.3K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $32K sold.
- 18 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q1 2017, down from 20 in Q4 2016.
- Funds reported $298K of Statera Biopharma, Inc. Common Stock stock for Q1 2017, down 2.6% quarter-over-quarter.
- 1 fund opened new Statera Biopharma, Inc. Common Stock positions in Q1 2017 and 1 closed out, a net change of 0 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q1 2017 was Renaissance Technologies, an estimated $38.3K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q1 2017 was Susquehanna International Group, an estimated $32K sold.
Based on aggregated 13F filings for Q1 2017.